You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Central Subfield Thickness

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diabetic Macular Edema Trial (Tonabersat, Placebo)

Not yet recruiting
  • Diabetic Macular Edema
  • (no location specified)
Feb 6, 2023

Fetal Membrane Thickness and Fetal Chromosomal Aneuploidies

Recruiting
  • Chromosome Aberrations
  • Ultrasound screening
  • Tianjin, Tianjin, China
    Tianjin Central Hospital of Obstetrics and Gynecology
Nov 15, 2023

Uveitis, Macular Edema Trial in Worldwide (Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg,

Completed
  • Uveitis
  • Macular Edema
  • Dexamethasone intravitreal implant 0.7 mg
  • +2 more
  • Los Angeles, California
  • +32 more
Mar 31, 2022

Assessment of the Occuity PM1 Pachymeter

Completed
  • Glaucoma Eye
    • Reading, Berkshire, United Kingdom
      Occuity Limited
    May 31, 2023

    Diabetic Macular Edema Trial (Bevacizumab Injection [Avastin] (IVB-I), Triamcinolone Acetonide 10mg/mL (IVT-II), Bevacizumab

    Completed
    • Diabetic Macular Edema
    • Bevacizumab Injection [Avastin] (IVB-I)
    • +2 more
    • (no location specified)
    May 24, 2022

    Skin Graft Scar, Split-Thickness Skin Graft (STSG) Trial in Central Jakarta (rhEGF)

    Completed
    • Skin Graft Scar
    • Split-Thickness Skin Graft (STSG)
    • Central Jakarta, DKI Jakarta, Indonesia
      RSPAD Gatot Soebroto
    Jul 19, 2022

    Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept Ophthalmic
    • IBI302
    • Suzhou, Jiangsu, China
      Innovent Biologics (Suzhou) Co,Ltd.
    Jul 25, 2023

    Diabetic Macular Edema Trial (K8)

    Not yet recruiting
    • Diabetic Macular Edema
    • (no location specified)
    Jan 27, 2023

    Neovascular Age-related Macular Degeneration Trial (AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • AXT107 Low Dose
    • +2 more
    • (no location specified)
    May 5, 2023

    Age-Related Macular Degeneration Trial (MG-O-1002, Placebo)

    Not yet recruiting
    • Age-Related Macular Degeneration
    • (no location specified)
    May 20, 2022

    Skin Transplantation Trial (FibDex®, Suprathel, Aquacel Foam)

    Not yet recruiting
    • Skin Transplantation
    • FibDex®
    • +2 more
    • (no location specified)
    Dec 23, 2022

    Non-proliferative Diabetic Retinopathy Trial (OTX-TKI, Sham)

    Not yet recruiting
    • Non-proliferative Diabetic Retinopathy
    • (no location specified)
    Jan 12, 2023

    Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio to

    Completed
    • Chronic Kidney Diseases
    • +2 more
      • Surakarta, Central Java, Indonesia
        RS UNS (Universitas Sebelas Maret Hospital)
      Jul 21, 2022

      Neovascular Age-Related Macular Degeneration Trial in China (Brolucizumab 6mg, Aflibercept 2 mg)

      Recruiting
      • Neovascular Age-Related Macular Degeneration
      • Brolucizumab 6mg
      • Aflibercept 2 mg
      • Guangzhou, Guangdong, China
      • +30 more
      Jan 20, 2023

      Macular Polypoidal Choroidal Vasculopathy (PCV) Trial in Korea, Republic of (Brolucizumab 6mg)

      Not yet recruiting
      • Macular Polypoidal Choroidal Vasculopathy (PCV)
      • Brolucizumab 6mg
      • Busan, Korea, Republic of
      • +13 more
      Dec 19, 2022

      Diabetic Macular Edema Trial (Faricimab)

      Not yet recruiting
      • Diabetic Macular Edema
      • (no location specified)
      Jan 20, 2023

      Diabetic Macular Edema Trial in Puerto Rico, United States (CU06-1004)

      Recruiting
      • Diabetic Macular Edema
      • Baltimore, Maryland
      • +9 more
      Dec 13, 2022

      Diabetic Macular Edema Trial (RC-28E, Aflibercept)

      Not yet recruiting
      • Diabetic Macular Edema
      • RC-28E
      • Aflibercept
      • (no location specified)
      May 30, 2023

      Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative Trial (OCS-01)

      Not yet recruiting
      • Uveitis Related Cystoid Macular Edema
      • Cystoid Macular Edema, Postoperative
      • (no location specified)
      Nov 1, 2022

      Diabetic Macular Edema Trial in Austin (Experimental: Group 1, Experimental: Group 2, Experimental: Group 3)

      Recruiting
      • Diabetic Macular Edema
      • Experimental: Group 1
      • +3 more
      • Austin, Texas
        Rezolute Investigative Site, Austin, TX
      Jan 31, 2023

      Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Austin (AIV007)

      Not yet recruiting
      • Neovascular Age-related Macular Degeneration
      • Diabetic Macular Edema
      • Austin, Texas
        Retina Consultants of Austin
      Jan 16, 2023

      X-linked Retinoschisis Trial in Shanghai (LX103 Injection)

      Recruiting
      • X-linked Retinoschisis
      • LX103 Injection
      • Shanghai, China
        Shanghai General Hospital, Shanghai Jiao Tong University
      Apr 4, 2023

      Neovascular Age-related Macular Degeneration (nAMD) Trial (AR-14034 SR implant lower dose, Aflibercept Injection, Sham

      Not yet recruiting
      • Neovascular Age-related Macular Degeneration (nAMD)
      • AR-14034 SR implant lower dose
      • +3 more
      • (no location specified)
      Mar 3, 2023

      Uveitis, Posterior Trial in United States (Fluocinolone Acetonide Intravitreal Implant 0.18 mg)

      Recruiting
      • Uveitis, Posterior
      • Fluocinolone Acetonide Intravitreal Implant 0.18 mg
      • Phoenix, Arizona
      • +16 more
      Aug 18, 2022

      Macular Edema Due to Diabetes Trial (Metaverse-assisted home OCT monitoring model, Hospital-based monitoring with a

      Not yet recruiting
      • Macular Edema Due to Diabetes Mellitus
      • Metaverse-assisted home OCT monitoring model
      • Hospital-based monitoring with a staff-administrated OCT
      • (no location specified)
      Feb 3, 2022